Cohen and Associates is a highly respected neuropsychiatry clinic in western Florida
HOPE Therapeutics, a multi-site clinical care delivery organization and wholly-owned subsidiary of NRx Pharmaceuticals, a clinical-stage biopharmaceutical company, announced the signing of a binding Letter of Intent to purchase a 49% interest in Cohen and Associates, founded by Dr. Rebecca Cohen. Cohen is expected to serve as a foundational clinic for HOPE in the Sarasota-Bradenton region of western Florida.
Cohen is one of the premier Interventional Psychiatry clinics in the region. The clinic offers a full range of treatments for suicidal depression, PTSD and other CNS disorders, including ketamine, Spravato, Transcranial Magnetic Stimulation as well as medication management.
Health Technology Insights: Infinitus and Salesforce Boost AI Adoption in Healthcare
Dr. Cohen is an Interventional Psychiatrist and Psychopharmacologist specializing in the treatment of mood and anxiety disorders as well as a nationally recognized expert in TMS. Her practice was established in 2014 to deliver top tier Psychiatric evaluations and comprehensive clinical care. She has expanded the scope of her practice with the addition of outstanding colleagues and technologies to deliver the most evidence-based and compassionate care in the region. Dr. Cohen’s academic background spans Tufts University, Boston University, where she was recipient of the psychiatry department’s Malamud Award for Excellence and Georgetown University. Dr Cohen has been honored as a Fellow of both the American Psychiatric Association and the International Clinical TMS Society.
Health Technology Insights: Bio-Thera Begins Phase 3 Trial for BAT8006 in Ovarian Cancer
“We are delighted to welcome Rebecca and her team to the HOPE family. Her extensive experience with neuroplastic therapies, combined with compassionate patient care exemplify our culture of bringing HOPE to life,” said Jonathan Javitt, MD MPH and Matthew Duffy, Co-CEOs of HOPE Therapeutics.
“I am thrilled to be working with HOPE at this exciting juncture in the company’s evolution. Our goal will always be to deliver outstanding patient care by offering the best available treatments and individualized care,” stated Dr. Cohen.
The potential acquisition of Cohen is subject to the execution of definitive transaction documents and standard closing requirements. Further details regarding the terms of the transaction will be disclosed at that time.
Health Technology Insights: Telix Manufacturing Solutions Belgium Delivers First GMP-Grade Commercial Doses
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source – PR Newswire
